Connect with us

Technology

Cancer Diagnostics Market to Reach US$ 41.5 Billion by 2031 at 7.2% CAGR, says Wissen Research

Published

1 day ago

on

SHERIDAN, Wyo., Oct. 15, 2026 /PRNewswire/ — The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031, growing at a CAGR of 7.2% over the forecast period (2026–2031), according to a new study by Wissen Research.

The starting point is simple: more people need testing. The International Agency for Research on Cancer (IARC) counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects annual new cases to pass 35 million by 2050. Every one of those patients may need screening, diagnosis, staging, molecular characterization, and follow-up, so the load on diagnostic tools keeps building.

What is changing faster is how the testing gets done. Diagnosis that once leaned mostly on imaging and a pathologist’s reading of tissue is becoming a layered process that also draws on digital pathology, molecular and genomic tests, liquid biopsy, and AI.

Get a Free Sample of This Report to Explore Key Findings and Data: https://www.wissenresearch.com/request-a-sample/?report=cancer-diagnostics-market 

Diagnosis Is Becoming a Stack: Imaging and Pathology Now Share the Work With Molecular and AI Tools

Mammography, CT, MRI, and tissue pathology are still the backbone of cancer diagnosis. Pathology in particular remains central, since examining tissue and cells under the microscope is how a cancer is confirmed, and immunohistochemistry adds protein-level detail that helps pin down the tumor type and the right therapy. What the report highlights is the layer being added on top. According to the National Cancer Institute, an advanced diagnosis now tells clinicians not only where the cancer is and how far it has spread, but also what type it is and which genetic and molecular changes could influence treatment.

That is where precision oncology comes in. Molecular testing is used to profile tumors and find markers that guide treatment, and next-generation sequencing based comprehensive genomic profiling lets labs look at several biomarkers from a single sample. The FDA’s list of companion diagnostics, which identify patients likely to benefit from a particular therapy, those at risk of severe side effects, or how well a treatment is working, is increasingly populated with NGS and liquid biopsy tests. AI is joining the mix as well. Tools are being built for medical imaging, digital pathology, and lesion detection and classification, the FDA has approved AI systems for medical use, and the NCI continues to advance research on AI in cancer imaging.

Liquid Biopsy Is Moving Up, But Tissue Isn’t Going Anywhere

Liquid biopsy is fast becoming an important tool because it can pick up signs of cancer in blood or other body fluids instead of requiring a tissue sample each time. The NCI describes it as testing blood for cancer cells or pieces of tumor DNA, with uses that include diagnosis, treatment decisions, tracking response, and spotting recurrence. The FDA has already approved liquid biopsy companion diagnostics, including tests that use NGS to analyze circulating DNA from plasma.

The report is careful about the limits, though. Liquid biopsy is not yet ready to replace tissue-based diagnostics across the board, and questions about sensitivity, specificity, clinical utility, and validation remain open. The same caution applies to multi-cancer detection tests, where the NCI is still studying how they should fit into screening and what they would mean for patient outcomes.

What’s Fueling Growth in the Cancer Diagnostics Market

More patients to test: Demographic change is expanding the number of people who need screening, diagnosis, staging, and monitoring.A push for earlier detection: The WHO separates early diagnosis in people with symptoms from screening in people without them, and says earlier detection leads to better treatment outcomes. Screening for breast, cervical, colorectal, and lung cancer keeps imaging, cytology, and other tests in steady demand.Precision oncology: Molecular testing is now used to profile tumors and find markers that decide treatment, lifting demand for molecular and biomarker diagnostics.Genomic testing and liquid biopsy: NGS-based profiling checks multiple genetic changes at once, while liquid biopsy looks at tumor-derived DNA in blood or other fluids.AI and digitalization: AI is being developed for medical imaging, digital pathology, lesion detection and classification, and handling complex diagnostic data.Asia Pacific build-out: New hospitals, diagnostic labs, and cancer hospitals, along with public screening programs, are widening access to modern diagnostics across the region.

Challenges Facing the Cancer Diagnostics Market

A new cancer test has to clear a high bar before it earns clinical trust. Developers contend with diagnostic accuracy, sample quality, tumor heterogeneity, biomarker variability, false positives and false negatives, turnaround time, reimbursement, data interoperability, and regulatory requirements. Each technology has its own version of the problem. Molecular testing can be limited by scarce tissue and by tumors that contain genetically distinct populations. Liquid biopsy has to detect very low concentrations of tumor material. AI tools for imaging and pathology need the right datasets and proper clinical validation.

There is also a harder question behind the technical ones. A test can reveal a biomarker or an abnormality without proving that using it improves patient outcomes, which is why clinical utility matters so much for newer approaches such as multi-cancer detection.

Recent Strategic Developments in the Cancer Diagnostics Market

On September 28, 2026, Leica Biosystems, a subsidiary of Danaher Corporation, completed its acquisition of StatLab Medical Products. The deal widens Leica’s anatomic pathology portfolio across specimen collection, preparation, staining, digital imaging, and AI-enabled diagnosis, strengthening its end-to-end pathology capabilities and supporting faster, more standardized cancer diagnostic workflows.

On July 27, 2026, Siemens Healthineers AG and Vanderbilt Health entered an $87 million multi-year partnership to modernize diagnostic imaging and radiation oncology. The agreement covers MRI, CT, molecular imaging, and interventional radiology systems, and advances AI-enabled radiology, personalized medicine, and workflow automation.

On May 7, 2026, F. Hoffmann-La Roche Ltd entered a definitive agreement to acquire PathAI for up to $1.05 billion, including $750 million upfront and milestone payments. The acquisition was expected to strengthen Roche’s digital pathology and AI capabilities by integrating PathAI’s AI-powered pathology platform with Roche’s oncology diagnostics and companion diagnostics portfolio.

Taken together, the three deals put money behind pathology, imaging, and AI-enabled workflows.

Key Insights from Cancer Diagnostics Market Analysis

IVD testing held the largest share by product type in 2025, reflecting how widely laboratory testing is used for diagnosis, disease characterization, biomarker assessment, and treatment decisions. The category covers kits and reagents, PCR and NGS instruments, in situ hybridization, immunohistochemistry, and other laboratory technologies.Diagnosis and disease characterization held the largest share by application in 2025, because malignancy has to be confirmed and its biology characterized before treatment begins. Molecular and genomic testing identifies mutations, gene fusions, biomarker expression, microsatellite instability, and mismatch-repair status that can steer treatment choice.North America held the largest regional share in 2025, supported by advanced medical infrastructure, established cancer-screening programs, advanced imaging and laboratory technology, molecular diagnostics, and a number of global diagnostic and medical-device leaders.Asia Pacific is the fastest-growing region, driven by a rising cancer burden, better healthcare infrastructure, and investment in diagnostic facilities.The market is moderately consolidated in established diagnostic technologies but remains fragmented across emerging molecular, liquid biopsy, digital pathology, and AI-enabled applications, where major diagnostic and life-sciences companies compete alongside specialized molecular-diagnostic and oncology-focused technology companies.

Key Players in the Cancer Diagnostics Market

Leading companies in the cancer diagnostics market are focusing on medical imaging, pathology, molecular diagnostics, genomic testing, companion diagnostics, liquid biopsy, cancer screening, digital pathology, artificial intelligence, and expansion of precision-oncology testing.

The report names F. Hoffmann-La Roche, Danaher, Abbott Laboratories, Thermo Fisher Scientific, and Siemens Healthineers as the top five players, with established positions across pathology, molecular diagnostics, genomic testing, medical imaging, biomarker testing, laboratory diagnostics, and precision oncology. Recent moves show where several of them are heading:

Roche (Switzerland): digital pathology, AI, and companion diagnostics, reinforced by its agreement to acquire PathAI.Danaher (US): anatomic pathology through Leica Biosystems and its StatLab acquisition.Siemens Healthineers (Germany): diagnostic imaging and radiation oncology, including its partnership with Vanderbilt Health.Abbott (US) and Thermo Fisher Scientific (US): also in the top five, and, along with GE HealthCare and Hologic, among the companies the report points to as active in North America.

Other companies covered in the report include QIAGEN, Illumina, Agilent Technologies, Becton Dickinson, Exact Sciences, Guardant Health, Natera, GRAIL, and Tempus AI.

Regional Analysis and Growth Opportunities

North America leads the cancer diagnostics market. The U.S. has a well-built regulatory and clinical environment for the field, with the FDA overseeing laboratory diagnostic devices, imaging technologies, and companion diagnostics. The region also combines a large cancer patient population, developed screening systems, advanced diagnostic laboratories, precision oncology programs, and high healthcare spending. Roche, Danaher, Abbott, Thermo Fisher Scientific, GE HealthCare, and Hologic are among the companies the report points to as active in cancer diagnostics.

Asia Pacific is expected to grow rapidly, mainly because of a rising cancer burden, better healthcare infrastructure, and investment in diagnostic facilities. New hospitals, diagnostic labs, and cancer hospitals have made modern diagnostic processes more accessible, and as healthcare becomes more digital, more stakeholders are adopting molecular diagnosis, gene testing, digital diagnostics, and advanced imaging. Public cancer screening programs, health awareness campaigns, and more private healthcare facilities add to the momentum.

Europe, Latin America, and the Middle East & Africa complete the report’s regional coverage.

Need Insights Specific to Your Business? Request a Customized Version of This Report

Market Segmentation Snapshot

The global cancer diagnostics market is segmented across product type, technology type, tumor type, application type, end-use industry type, and region:

By Product Type:Anatomic Pathology (Instruments: Slide Staining Systems, Tissue Processing Systems, Cell Processors, Microtomes, Embedding Systems, Cover Slippers, Digital Pathology Scanners, Other Anatomic Pathology Instruments; Consumables: Antibodies, Kits & Reagents, Probes, Other Consumables)IVD Testing (Kits & Reagents; Instruments: PCR Instruments, NGS Instruments, Microarrays; In Situ Hybridization; Immunohistochemistry; Immunoassay; Flow Cytometry; Other IVD Testing Instruments)Imaging-Based (Instruments: CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, PET-CT)Consumables (Contrast Agents, Radiopharmaceuticals)By Technology Type:Imaging Technologies (Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography, Mammography, Ultrasound)Anatomic Pathology (Histopathology, Cytopathology)IVD Testing (Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, Immunoassay, Microarray, Flow Cytometry, Other IVD Technologies)BiopsiesBy Tumors Type:Hematologic / Liquid TumorsSolid TumorsBy Application Type:Treatment Decision SupportTreatment Monitoring & Disease Progression AssessmentPost-Treatment Surveillance & Recurrence DetectionScreening & Early DetectionDiagnosis & Disease CharacterizationBy End Use Industry Type:Hospitals & ClinicsDiagnostic LaboratoriesBy Region:North AmericaEuropeAsia-PacificLatin AmericaMiddle East & Africa

Frequently Asked Questions

Q: What is the size of the cancer diagnostics market? A: The global cancer diagnostics market is estimated at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031.

Q: What is the growth rate of the cancer diagnostics market? A: The cancer diagnostics market is projected to grow at a CAGR of 7.2% between 2026 and 2031.

Q: What is cancer diagnostics? A: Cancer diagnostics refers to the diagnostic products, technologies, and testing services used to detect, confirm, characterize, stage, monitor, and assess cancer and related disease biomarkers. It spans imaging-based diagnostics, in vitro diagnostic (IVD) testing, anatomic pathology, molecular and genomic testing, immunohistochemistry, immunoassays, cytology, and other technologies used across the cancer care pathway.

Q: Which product type leads the cancer diagnostics market? A: IVD testing held the largest share by product type in 2025, driven by the widespread use of laboratory testing for diagnosis, disease characterization, biomarker assessment, and treatment decisions.

Q: Which application leads the cancer diagnostics market? A: Diagnosis and disease characterization held the largest share by application in 2025, because malignancy must be confirmed and its biological and clinical features characterized before treatment.

Q: Which region leads the cancer diagnostics market? A: North America held the largest share of the cancer diagnostics market in 2025, while Asia Pacific is the fastest-growing region through 2031.

Q: Who are the top players in the cancer diagnostics market? A: Leading companies in the cancer diagnostics market include F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., and Siemens Healthineers AG, which have established positions across pathology, molecular diagnostics, genomic testing, medical imaging, biomarker testing, laboratory diagnostics, and precision oncology.

Q: What is a liquid biopsy? A: According to the National Cancer Institute, a liquid biopsy tests blood for cancer cells or pieces of DNA from tumors. It can help with diagnosis, treatment decisions, evaluating treatment response, and identifying recurrence, but it is not yet ready to replace tissue-based diagnostics universally.

Mammography, CT, MRI, and pathology remain the backbone of cancer diagnosis. What the report points to is a process that layers molecular, digital, and AI-based tools on top of them, and that is where companies are putting their money. For manufacturers and laboratories, the work ahead is proving that the newer tests deliver accurate, validated results that improve patient outcomes.

Get the Complete Cancer Diagnostics Market Report — Forecasts, Insights & Growth Opportunities: https://www.wissenresearch.com/market-research-reports-pricings/cancer-diagnostics-market

Expert Profile | Mayur Jain, Wissen Research 

Mayur Jain is a Research Expert at Wissen Research with multidomain expertise with more than 12+ years of experience in market research industry. 

Email: mayur@wissenresearch.com
LinkedIn:  https://www.linkedin.com/in/mayur-jain-0190542a/ 

About Wissen Research

Wissen Research is a global market intelligence and consulting firm specializing in healthcare, life sciences, technology, and emerging industries. The company provides data-driven insights, strategic market analysis, and industry forecasts to help organizations make informed business decisions and identify new growth opportunities across global markets

Company Contact:

Wissen Research LLC,
Gould St, Ste R,
Sheridan, WY 82801,
Phone: (+1) 510 240 9853
Email: info@wissenresearch.com
Website: https://www.wissenresearch.com/
Blog: https://www.wissenresearch.com/insights/
LinkedIn: https://www.linkedin.com/company/wissen-research 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-diagnostics-market-to-reach-us-41-5-billion-by-2031-at-7-2-cagr-says-wissen-research-302910613.html

SOURCE Wissen Research LLC

Related Topics:
Continue Reading

Technology

Canada to advance global nature conservation and climate action at upcoming United Nations conferences

Published

2 hours ago

on

October 16, 2026

By

OTTAWA, ON, Oct. 16, 2026 /CNW/ — In a more uncertain and increasingly unstable world, Canada is stepping up to build a safer and more resilient future. Addressing climate change and biodiversity loss requires ambitious action at home and around the world. By advancing progress on both, Canada will protect nature, build resilient communities, and create lasting prosperity for future generations. International cooperation is key to achieving these goals.

That is why the Honourable Julie Dabrusin, Minister of the Environment, Climate Change and Nature, will lead Canada’s efforts as Head of Delegation at the 17th meeting of the Conference of the Parties to the Convention on Biological Diversity (COP17) and the 31st meeting of the Conference of the Parties to the United Nations Framework Convention on Climate Change (COP31).

At COP17, Minister Dabrusin and the Honourable Nathalie Provost, Secretary of State (Nature), will work with international partners to accelerate implementation of the Kunming–Montréal Global Biodiversity Framework. From October 19 to 30, 2026, in Yerevan, Armenia, Canada will champion the critical role of Indigenous peoples in conservation and advocate for practical solutions to mobilize global resources for biodiversity finance. Canada will showcase its leadership through two Canadian-led official side events focused on innovative nature finance and the essential role of Indigenous leadership in advancing conservation efforts at home and around the world. The delegation will also take part in strategic bilateral meetings, high-level roundtables, and civil society events to strengthen cooperation, advance solutions, and drive action to halt and reverse biodiversity loss.

From November 9 to 20, 2026, in Antalya, Türkiye, Canada will participate in the 31st Conference of the Parties to the United Nations Framework Convention on Climate Change (COP31). Building on multilateral engagements, including the 10th Ministerial on Climate Action, Canada will continue working with international partners, Indigenous representatives, civil society, youth, and other stakeholders to strengthen the resilience of vulnerable communities; reduce methane emissions; accelerate electrification; and mobilize finance and investments from public and private sources. For the fifth consecutive year, Canada will host a national pavilion at COP31, showcasing Canadian climate leadership and innovation. The Canada Pavilion will serve as a hub for connection and collaboration.

Canada’s international leadership is backed by action at home. To accelerate electrification, Canada is building major clean energy projects across the country, including with the largest clean energy investment in North American history in Churchill Falls. Through A Force of Nature: Canada’s Strategy to Protect Nature and $3.8 billion in investments and funding, Canada is advancing its commitment to conserve 30% of lands and waters by 2030 through strong partnerships and innovative approaches to conservation. Canada recently reinforced this commitment by joining the 30×30 for Nature and People Ministerial Declaration at the 81st session of the United Nations General Assembly. Prime Minister, Mark Carney, recently announced a historic investment of $1.2 billion to better protect Canada’s oceans and the life they sustain. This will increase monitoring, strengthen ocean science and ecosystem protections, and improve marine incident prevention and preparedness. These priorities will be a key focus at both upcoming conferences.

Canada’s delegations to COP17 and COP31 will bring together the diverse perspectives from across Canadian society, including Indigenous representatives, civil society, the private sector, youth, and provincial and territorial government representatives. Working with international partners, these delegations help advance practical solutions to protect nature, strengthen resilience, and support sustainable economic prosperity.

Quotes

“Climate change and biodiversity loss are global challenges that no country can solve alone. At COP17 and COP31, Canada will work with partners from around the world to strengthen implementation of the Kunming–Montréal Global Biodiversity Framework and the Paris Agreement and collective efforts to address nature protection and climate change. Through international cooperation, Indigenous leadership, innovative solutions, and a collective commitment to conservation and climate action, we will build a sustainable future for people and nature alike.”
– The Honourable Julie Dabrusin, Minister of the Environment, Climate Change and Nature

“Nature loss is a global challenge that requires countries to work together and turn shared commitments into action. At COP17, Canada will share its experiences in advancing nature finance, including innovative approaches to valuing natural capital and mobilizing private investment for conservation. By exchanging ideas, lessons learned, and practical solutions with international partners, we can accelerate progress toward our global biodiversity goals and recognize nature as a foundation of long-term economic prosperity and resilience.”
– The Honourable Nathalie Provost, Secretary of State (Nature)

Quick facts

As the second largest country in the world, Canada has a vast amount of natural capital, including 24% of the world’s boreal forest, 37% of lakes, 25% of wetlands, and approximately 80,000 species. We have both a responsibility to steward these resources as well as a competitive advantage because of these assets.Canada hosted the 15th meeting of the Conference of the Parties to the United Nations Convention on Biological Diversity (COP15) in Montréal in 2022, which resulted in the adoption of the Kunming–Montréal Global Biodiversity Framework: an ambitious global plan to halt and reverse biodiversity loss by 2030.Canada supports the Armenian COP17 presidency and its approach to strengthen implementation of the Kunming–Montréal Global Biodiversity Framework toward meeting the Framework’s goals and targets.In September 2026, Canada and China co-chaired the Kunming Dialogue in Kunming, China. The Dialogue was a multilateral working-level meeting to discuss progress and challenges in the implementation of the Framework ahead of COP17.The Canada Pavilion at the United Nations Conference of the Parties (COP) is a key space to show Canadian climate leadership and innovation.Reducing methane emissions remains one of the fastest and most cost-effective ways to limit the rise of near-term global temperatures. Canada serves as co-convenor of the Global Methane Pledge, which counts 159 participating countries and the European Commission, with participants agreeing to take voluntary actions toward a collective goal of reducing global methane emissions at least 30% by 2030 (from 2020 levels).In April 2026, Canada announced a new goal of delivering $13 billion in international climate finance over the next five years.

Associated links

A Force of Nature: Canada’s Strategy to Protect NaturePrime Minister Carney Announces Historic Investment to Protect Canada’s OceansCanada Pavilion at the Conference of the Parties (COP)

Environment and Climate Change Canada’s X page
Environment and Climate Change Canada’s Facebook page
Environment and Natural Resources in Canada’s Facebook page
Environment and Climate Change Canada’s LinkedIn page
Environment and Climate Change Canada’s Instagram page

SOURCE Environment and Climate Change Canada

Continue Reading

Technology

DGEN TECHNOLOGIES (FORMERLY CHINA KELI ELECTRIC COMPANY) COMPLETES ACQUISITION AND NAME CHANGE AND FILES CSE LISTING STATEMENT

Published

2 hours ago

on

October 16, 2026

By

VANCOUVER, BC, Oct. 16, 2026 /CNW/ — DGEN Technologies Corp. (formerly China Keli Electric Company Ltd.) (the “Company”) is pleased to announce that it has completed its previously announced acquisition of DGEN Financial Holdings Corp. (formerly DGEN Technologies Corp.) (“DGEN”) pursuant to a share exchange agreement dated December 9, 2025, as amended on August 17, 2026 (the “SEA”) on October 14, 2026 (the “Transaction”).

Pursuant to the Transaction, the Company acquired all of the issued and outstanding shares of DGEN in exchange for the issuance of an aggregate of 9,550,360 common shares of the Company (“Common Shares”) and 7,000,360 Common Share purchase warrants (“Warrants”) to certain former shareholders of DGEN. Each Warrant entitles the holder to acquire one Common Share at a price of $0.25 until October 14, 2028. As a result of the Transaction, DGEN became a wholly-owned subsidiary of the Company. As of the date hereof, the Company has 29,161,364 Common Shares and 7,000,360 Warrants issued and outstanding.

In connection with the completion of the Transaction, the Company changed its name from “China Keli Electric Company Ltd.” to “DGEN Technologies Corp.” and, hereinafter, will carry on the business of DGEN.

Listing Statement

Following the closing of the Transaction, the Company has filed a CSE Form 2A listing statement dated October 14, 2026 (the “Listing Statement”) on SEDAR+ under its profile relating to the Transaction and the proposed CSE listing. Investors are encouraged to review the Listing Statement, which provides detailed information about the Transaction, the Company and its operations.

The Company has received conditional approval to list the Common Shares on the Canadian Securities Exchange (the “CSE”) and has delisted the Common Shares from the TSX Venture Exchange in anticipation of listing on the CSE. The Common Shares are expected to commence trading on the CSE under the symbol “DGEN” on or about October 20, 2026.

Board of Directors and Management

Following completion of the Transaction, the directors and officers of the Company are Cole Goodwin, Chief Executive Officer and Director, Philip Lo, Chief Financial Officer, Corporate Secretary and Director, Sean Webster, Director, and Yee Man Cheung, Director.

Mr. Goodwin is a business executive with over 10 years of experience in alternative and traditional investment markets, financial technology and corporate operations. His experience includes senior management and board roles with publicly traded companies, including as Chief Operating Officer of Hyper Bit Technologies Ltd. Mr. Goodwin provides the Company with strategic and operational oversight in respect of its technology platform, including development and commercialization of payment infrastructure, integration of payment gateways, technology deployment and vendor management.

Escrow

At the time of listing, the Company will have 2,496,000 Common Shares and 1,000,000 Warrants held by related persons subject to escrow pursuant to an escrow agreement dated October 14, 2026 among the escrowed securityholders, the Company and Odyssey Trust Company, as escrow agent, subject to a 36-month release schedule pursuant to National Policy 46-201 – Escrow for Initial Public Offerings.

About DGEN Technologies Corp.

DGEN Technologies Corp. is a Vancouver-based technology company developing a cloud-based payment platform intended to integrate point-of-sale, kiosk and mobile payment systems into a unified and scalable solution. The Company’s platform is currently in beta stage and is operational, but has not yet been commercialized or generated revenue.

The CSE has not reviewed, approved, or disapproved, and does not accept responsibility for the adequacy or accuracy of the contents of this news release.

Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including, without limitation, statements with respect to: the expected listing of the Common Shares on the CSE; the satisfaction of any remaining conditions to listing; the business and operations of the Company following completion of the Transaction; the Company’s platform, including its development, commercialization, functionality, market adoption and ability to generate revenue; the Company’s intended business objectives; the escrow arrangements applicable to certain Common Shares and Warrants; and future plans and expectations of the Company. Forward-looking information is based on management’s current expectations, estimates, projections, beliefs and assumptions as of the date of this news release.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the possibility that the Common Shares may not commence trading on the CSE when expected or at all; risks relating to the Company’s early stage of development; the fact that the platform is in beta stage, has not yet been commercialized and has not generated revenue; risks associated with development, commercialization and market adoption of the platform; competition from established payment technology providers; reliance on third-party contractors and service providers; additional financing and dilution risks; market volatility; regulatory, compliance, cybersecurity and data privacy risks; risks relating to escrowed securities; and the other risks described in the Listing Statement. Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this news release. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE DGEN Technologies Corp.

Continue Reading

Technology

ASSA ABLOY sells PKI business unit to Vista Equity Partners

Published

3 hours ago

on

October 16, 2026

By

STOCKHOLM, Oct. 16, 2026 /PRNewswire/ — ASSA ABLOY has signed an agreement to sell HID’s PKI business unit to Vista Equity Partners (“Vista”).

The PKI business unit (Public Key Infrastructure) provides digital trust, identity, authentication, encryption, and certificate management solutions. The business unit includes PKI SaaS – IdenTrust and HydrantID – credential management, and ZeroSSL.

“I find it very satisfying that with Vista, the PKI business unit and its employees and customers gain a committed long-term investor, creating new opportunities for the future and I wish them every success,” says Nico Delvaux, President and CEO of ASSA ABLOY.

“Our PKI team has built a strong business with a strong customer base, and Vista has the expertise to take it forward as the market evolves,” says Björn Lidefelt, EVP and Head of HID. “We are pleased with this outcome for our customers, our employees, and for HID.”

The divested business had sales in 2025 of MUSD 58 (approx. MSEK 570) with a strong operating margin.

The divestiture is subject to customary closing conditions and is expected to close during the fourth quarter of 2026.

For more information, please contact: 
Nico Delvaux, President and CEO, tel. no: +46 8 506 485 82
Erik Pieder, CFO and Executive Vice President, tel. no: +46 8 506 485 72
Björn Tibell, Head of Investor Relations, tel. no: +46 70 275 67 68, e-mail: bjorn.tibell@assaabloy.com

About ASSA ABLOY
ASSA ABLOY is the global leader in access solutions. Every day we help people feel safe, secure and experience a more open world. We operate worldwide with 64,000 employees and sales of SEK 152 billion, with leading positions in areas such as efficient door openings, trusted identities and entrance automation. Our innovations enable safe, secure and convenient access to physical and digital places.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/assa-abloy/r/assa-abloy-sells-pki-business-unit-to-vista-equity-partners,c4410007

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/assa-abloy-sells-pki-business-unit-to-vista-equity-partners-302911635.html

Continue Reading

Trending